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Eltoprazine, a drug that had previously been developed for aggression, has recently been investigated for L‑DOPA‑induced dyskinesia 
in animal models of Parkinson´s disease (PD) and in dyskinetic PD patients. Much less is known about effects of eltoprazine in other 
therapeutic indications. Indeed, the pharmacological profile of eltoprazine might suggest its effects on anxiety and food intake, but also 
adverse effect potential, which is the focus of the present study. 
Given for 2 weeks either as infusion or as twice‑daily treatment, eltoprazine produced a decrease in food intake and body weight at 
doses leading to 200–500 nM plasma concentrations. 
In the elevated plus maze eltoprazine increased anxiety‑like behavior. On the other hand, it induced a clear‑cut anxiolytic effect in 
context fear conditioning test starting at ca. 0.3 mg/kg, and failed to produce any significant effect in fear potentiated startle test. 
Regarding adverse effects, eltoprazine was found to produce hypothermia starting from 1 mg/kg. At similar doses it also increased 
locomotion in the open field. However, eltoprazine failed to affect acquisition in context fear conditioning paradigm, which may indicate 
lack of its detrimental effect on learning at the doses tested (i.e., up to 5 mg/kg).
In summary, effects of eltoprazine in different anxiety tests were equivocal while its effect on body weight seems robust and requires 
further investigation. It is to be determined whether these effects can be expected at the doses free of adverse effects.
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INTRODUCTION
Eltoprazine (1‑(2,3‑dihydro‑1,4‑benzodioxin‑8‑yl)piperazine) 
is a compound with a plethora of activities at serotonergic 
(5‑HT) receptors, which has recently been developed for 
L‑DOPA‑induced dyskinesia in Parkinson’s disease. Eltoprazine 
is a partial agonist at 5‑H1A and 5‑HT1B receptors (with 
different intrinsic activities), a full agonist at 5‑HT2A receptors, 
a partial agonist at 5‑HT2B receptors and a full agonist at 
5‑HT2C receptors (Joels et al. 1990, Schipper et al. 1990). In turn, 
it can be supposed that the drug may have several potential 
therapeutic applications.
Eltoprazine was originally developed by Duphar and later 
by Solvay Pharmaceuticals for the treatment of aggression 
(Olivier et al. 1990) since it showed clear anti‑aggressive 
effects in dominant behavior assessment in rat colony as well 
as in animal models such as social interaction or predatory 
behavior (Olivier et al. 1990). Interestingly, in place 
conditioning, eltoprazine produced place aversion effect 
that was attenuated by mCPP (5‑HT1C agonist) suggesting 
that low intrinsic activity of eltoprazine at 5‑HT1C receptor 
may produce antagonistic‑like effect and contribute 
to emotional behavior (Rocha et al. 1993). However, 
5‑HT1A receptors also seem to play a role in aggression, 
since in intruder aggression test effect of eltoprazine 
was partially attenuated by the selective antagonist 
WAY‑100635 (N‑[2‑[4‑(2‑methoxyphenyl)‑1‑piperazinyl]
ethyl ] ‑N‑(2‑pir id inyl )  cyclohexanecarboxamide 
trihydrochloride) (de Boer et al. 1999).
In line with these observations, eltoprazine was shown 
to reduce aggression in intellectually disabled individuals, 
however this beneficial effect disappeared in the course of 
treatment (de Koning et al. 1994).
After Solvay’s merger with Abbott, the eltoprazine 
program was out‑licensed to PsychoGenics and the 
indication “adult ADHD” (attention deficit hyperactivity 
disorder in adults) was added based on the drug’s activity 
in PsychoGenics’ proprietary SmartCube® system, 
exhibiting a behavioral pattern similar to other stimulant 
and non‑stimulant drugs used in the treatment of ADHD 
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(http://www.psychogenics.com/newsletter/SmartCube/
repurposing.html).
Based on that, phase II trial in adult ADHD patients was 
performed providing encouraging results (http://www.
marketwatch.com/story/amarantus‑provides‑program‑
‑update‑on‑phase‑2b‑eltoprazine‑for‑parkinsons‑disease‑
‑and‑adult‑adhd‑2014‑09‑17). 
Eltoprazine also has been found to produce 
antidyskinetic effects in rats with unilateral lesion to 
the midbrain dopaminergic system and in MPTP treated 
macaques with some worsening of antiparkinsonian effect 
of L‑DOPA (Bezard et al. 2013). In turn, PsychoGenics 
added this indication and performed positive phase II 
trials (2012, Psychogenics.com). A further study sponsored 
by Michael J. Fox Foundation and PsychoGenics has 
recently been published (Svenningsson et al. 2015). Next, 
PsychoGenics out‑licensed eltoprazine to Amarantus 
that has been developing it further, apparently for all 
three aforementioned indications; however aggression 
has been limited to the one occurring in Alzheimer´s 
disease and phase II study results announced in December 
2015 indicated positive outcome. Recently, eltoprazine 
received orphan drug status from FDA for L‑DOPA‑induced 
dyskinesia.
Given the spectrum of these indications and 
eltoprazine’s unique pharmacological profile, i.e., its 
different modes of action at several serotonergic receptors, 
further indications for the drug can be envisaged. However, 
it should be stressed that adverse effect potential of 
eltoprazine has not yet been extensively evaluated. 
Moreover, anxiolytic effects of eltoprazine have been 
described (Sanchez 1997), but not intensively characterized 
and anorectic potential of substances acting at 5‑HT2C 
receptors has also been shown (Marston and Heisler 2009), 
albeit not specifically for eltoprazine.
Therefore the present study was aimed at testing 
anorexic and anxiolytic effects of eltoprazine as compared 
to adverse effects such as body temperature change, 
learning impairment and behavioral stimulation in 
laboratory rodents. The results have been previously been 
disclosed as a patent application (Valastro).
METHODS
Animals
In majority of experiments male Sprague‑Dawley rats 
weighing 180–200 g were used. In context fear conditioning 
experiments Sprague‑Dawley rats weighing 230–250 g were 
employed. The animals (317 in total) were kept up to four 
per cage (Polysulfone type IV, Tecniplast, Italy), with the 
exception of weight gain study, in a room with controlled 
temperature (21±1°C) and humidity (60±3%). Light was on 
6 a.m. till 6 p.m. Standard laboratory food (Altromin, Lage, 
Germany) and water were available ad libitum. The study 
was approved by the local Ethical Committee (Darmstadt, 
Hessen). The experiments were performed between 9 a.m. 
and 5 p.m.
Substances
Eltoprazine (1‑(2,3‑dihydro‑1,4‑benzodioxin‑8‑yl)piperazine) 
synthetized by Merz Pharmaceuticals, Frankfurt, Germany was 
dissolved in water (vehicle) and injected s.c. or delivered by 
osmotic pumps.
Weight gain experiments
The animals were either injected twice daily (b.i.d.) 
with eltoprazine (1 mg/kg) or implanted osmotic pumps 
(Alzet, 2ML2, USA) delivering 4.5 µl/h leading to a nominal 
daily dose of 8 mg/kg.
Osmotic ALZET pumps (DURECT Corporation, 
Cupertino, USA, Model 2ML2; mean pumping rate 
4.5 µl/h) were implanted subcutaneously. Briefly, rats were 
anaesthetized with 10% Metacam (inhalation anesthesia, 
isofluran/O2). The upper part of the animal back was shaved 
and disinfected, and a longitudinal incision (1 cm) of the 
skin was made with a scalpel to allow the subcutaneous 
insertion of an osmotic pump. The pump was positioned in 
the lower portion of the rat back. The incision was closed 
with three metal clips.
During the study, the animals kept in single cages were 
weighed daily between 7.00 and 9.00 and the amount of food 
ingested was assessed on working days at the same time. 
Blood samples were withdrawn by means of retrobulbar 
venous plexus puncture using micro‑hematocrit‑tubes 
(Heiland, Hamburg; Germany) and collected into 
Lithium‑Heparin tubes (Microvette® 500, Sarstedt, 
Nuembrecht, Germany). Subsequently, the samples were 
centrifuged (3000 rpm) for 10 minutes and plasma was 
carefully transferred to glass tubes and stored at −18°C 
until analysis of eltoprazine concentration.
Elevated plus maze (EPM)
The elevated plus maze made from black polypropylene 
consisted of two open arms (51×10 cm with 1.3 cm high 
walls), two closed arms (51×10 cm and 40.6 cm high 
walls) and a central platform (10×10 cm). The maze was 
elevated 72.4 cm above the floor and a 20 W normal light 
bulb was placed 33 cm above each of the open arms. In 
one experiment, red light 20 W bulb was used. Breaks of 
photo beams located in each arm entry were recorded and 
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analyzed automatically using an IBM‑PC running MED‑PC 
software version IV (Med Associates, St. Albans, Vermont, 
USA). A camera positioned 2 m above the maze allowed 
remote observation of rats’ behavior.
After 60 min habituation to the room, the animals were 
injected with eltoprazine or vehicle and 1 h later placed 
in the center of the maze facing an enclosed arm. Next, 
entries into closed and open arms, as well as the time spent 
in each type of arm, was recorded for 5 min.
Contextual fear condition (CFC) – anxiety and 
learning
For training and testing, rats were placed in a chamber 
(31×25×31 cm, w×d×h) equipped with a grid floor designed 
to deliver electric shocks (Coulbourn Instruments; 
Model H10‑11R‑TC‑SF, Whitehall, USA). The shocks were 
applied using electric shock generator and a scrambler. 
Application of the foot shocks and movement detection of 
the animals were performed using Freeze‑Frame software 
(version 1.62; Actimetrics, Wilmette, Illinois, USA). Test 
cages were placed in sound‑attenuating isolation cubicles 
(Coulbourn Instruments; Model H10‑24T, 64×51×66 cm, 
w×d×h) equipped with fans (Coulbourn Instruments; Model 
ACT‑130) producing background noise of 63 dB sound 
pressure level. An additional noise generator produced 
white noise to achieve overall background noise level of 
65 dB. Digital cameras (Panasonic, Secaucus, New Jersey, 
USA; Model WV‑BP334) were mounted on ceiling of test 
chambers to detect movements of animals.
For conditioning (training), rats were placed into the 
chambers and following a 2‑min habituation, 3 electric foot 
shocks (0.4 mA, 1 s) were delivered, with a 60‑s interval. 
Thirty seconds later the animals were removed from the 
chambers.
For testing, 24 h later the rats were placed again in 
the chambers and their freezing behavior was recorded 
for a total of 5 min. The percentage of time spent freezing 
during the 5‑min test was used for analysis. 
In the version of this test used to measure anxiety, 
eltoprazine was injected 1 h before test. For testing effect 
on acquisition of fear memory, the drug was injected 1 h 
before training.
Fear potentiated startle (FPS) 
Apparatus
For training, the subjects were placed in acrylic animal 
holders (19 cm long, 7.6 cm internal diameter (ID) with 
a grid floor consisting of 9 stainless steel bars (3 mm ID). The 
holders were fixed onto a startle platform (Med associates, 
Model PHM‑250B). The grid floor was connected to an electric 
shock generator and scrambler, by which a 0.6 mA foot shock 
was delivered. The complete equipment was placed into 
a sound‑attenuating chamber equipped with the speaker 
placed 7 cm from the animal holder in the back of the chamber 
and a fan attached on the side wall producing a background 
noise of 62 dB (together with background noise generator it 
was 64 dB). Startle‑eliciting noise 50 ms bursts were generated 
by a noise generator (Med associates, Model PHM‑255A). 
A 3.7 sec visual cue was produced by fluorescent stimulator 
(Med Associates, Model PHM‑258L) using a 8 W bulb, placed 
in front of the chamber. The output of the accelerometer was 
connected through an interface to an IBM‑PC running Startle 
Reflex software (Med associates, version 5.1).
Procedure 
Pre‑test 
On the first day, in order to obtain groups with similar 
startle responses, a pre‑test was performed. The subjects 
were placed into the acrylic holders, and after a 5 min 
acclimation, 6 initial startle stimuli (white noise, 100 dB, 
50 ms duration) were presented to induce a stable startle 
baseline. Then, each subject received 15 startle stimuli of 
100 dB (with 7–23 sec. inter‑stimulus interval). 
Conditioning 
For training 24 h later, the rats were placed back into 
the animal holders containing the grid floors. After a 5 min 
acclimation, 15 pairings of light with a 0.6 mA foot shock 
were presented. The unconditioned stimulus was presented 
during the last 500 ms of the 3.7 sec of light, so that both 
stimuli terminated together. The mean inter‑trial interval 
was 2 min with a range of 90–150 sec. 
Test 
24 h after conditioning, the rats again were placed into 
the animal holders. After a 5 min acclimation period, the 
animals received 6 initial noise bursts of 100 dB to establish 
a stable startle baseline before recording. Then, 24 startle 
stimuli (50 ms, 100 dB) were presented, half of them 
3200 ms after the onset of the light (light‑noise trials), and 
half of them in dark (noise alone trials). Inter‑trial interval 
was 15–45 sec. Differences of light‑noise and noise alone 
trials were calculated.
Body temperature
Body temperature was measured 60 min before 
injection, and then animals were randomized and 
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injected s.c. with eltoprazine (0.1, 0.3, 1, or 3 mg/kg,) or 
saline. Rectal temperature was measured 15, 30, 45 and 
60 min after treatment.
Open field
Rats were habituated to the experimental room for 
1 h prior to testing. Eltoprazine was administered and 
the animals were placed in open field boxes 1 h later 
and locomotor activity was measured in Perspex boxes 
(43.2×43.2×30 cm) placed in noise‑proof chambers with white 
light (5.6 W) placed 55 cm above the floor (Med‑Associates 
Inc. system, St. Albans, USA). Each chamber was equipped 
in 16 infrared photo beams 3 cm above the floor to measure 
horizontal activity. Two sets of 16 photo beams placed 15 cm 
above the floor level were employed to measure vertical 
activity. Box size was set to “4” (corresponds to a minimal 
number of photo beam interruptions resulting in counts) 
which precluded counting of stereotypy. Recording of beam 
interruptions was continued for 60 or 120 min in 10‑ or 
20‑min intervals (depending on an experiment). 
Statistics
All results were expressed as means ±SEM with 
exception of plasma levels, which were shown as individual 
values and their medians. Data were analysed by ANOVA 
followed by Dunnett’s test or ANOVA on ranks followed 
by Mann‑ Whitney test depending on values’ distribution. 
P<0.05 was regarded as significant.
RESULTS
Weight gain
Both infusion of eltoprazine (8 mg/kg/d) and injections 
twice daily (1 mg/kg) for 14 days produced sustained 
inhibition of weight gain (Fig. 1A, ANOVA F(3,28)=17,0 
p<0.001). The effect size was similar from day 4 to 14. There 
was trend for stronger effect following the infusion which 
is likely due to approximately 2 times higher plasma levels 
achieved after this mode of treatment (Fig. 2). Eltoprazine 
also affected food intake (Fig. 1B, ANOVA F(2,28)=11.1 
p<0.001), which can at least partly explain its effect on 
weight gain. 
Anxiety
In the elevated plus maze, eltoprazine surprisingly 
produced a decrease in time spent in open arms and in 
a number of open arm entries starting at 0.31 mg/kg (Fig. 3, 
ANOVA F(2,28)=6.1, P=0.003 and F(3,28)=3,9, p=0.019 for 
time in open arms and entries respectively), while having 
no effect on total entries. This indicates “anxiogenic‑like” 
effect with no change in general activity. As the bright 
light in a plus maze test is a major trigger to prevent 
animals from visiting open arms, we also repeated the 
test under red light conditions as rats do not perceive red 
light wavelengths. As expected, the time on open arms 
and number of visits to open arms were found to be much 
higher at these conditions (Fig. 4, ANOVA F(3,36)=5.7, 
p=0.003 and F(3,36)=13.9, P<0.001 for time in open arms and 
A B
Fig. 1. Effect of eltoprazine on weight gain (A) and food intake (B) in rats. The animals were either injected b.i.d. (1 mg/kg s.c.) or implanted osmotic pumps 
allowing constant drug delivery (8 mg/kg/day). The values are shown as mean ±SEM. The data were analyzed using two‑way ANOVA with time as repetitive 
measure, which showed significant effect of treatment, day and their interaction. # – P<0.05 vs. vehicle s.c. injected group; * – P<0.05 vs. vehicle infused 
group, Dunnett’s post‑hoc test. N=8 per group.
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entries respectively). However, eltoprazine still produced 
anxiogenic‑like effect. It should be noted that under red 
light conditions there was a modest, but significant increase 
in general activity (total arm entries) following the highest 
eltoprazine dose of 1 mg/kg (ANOVA F(3,36)=6.2, P=0.002).
In a further model of anxiety, context fear conditioning, 
a strong, dose‑dependent decrease in the freezing time 
after eltoprazine was observed, suggesting anxiolytic‑like 
activity (Fig. 5, ANOVA on ranks H=12.58 with 3 degrees of 
freedom, p=0.006). A significant effect was achieved already 
at 0.078 mg/kg.
In contrast, in yet another model of anxiety, fear 
potentiated startle, eltoprazine failed to produce 
a significant effect at doses up to 1 mg/kg (Fig. 6, ANOVA 
F(3,33)=0.51, P=0.68). The drug also failed to affect acoustic 
startle reaction alone.
Adverse effects
Eltoprazine at low dose (0.1 mg/kg) produced slight 
hyperthermia, which was however significant at just 
one time point (30 min). In contrast, at higher doses, the 
drug induced dose‑dependent hypothermia reaching 
significance at 1 mg/kg (Fig. 7, ANOVA F(4,20)=8.1 p<0.001).
In the open field test, eltoprazine produced an increase 
in activity, which at lower doses was only evident during 
first recording period (20 min). However at a high dose of 
10 mg/kg was significant for the entire observation period, 
i.e., 120 min (Figs 8A, 8C, ANOVA F(3,28)=19.28, p<0.001 and 
F(3,28)=34.76, p<0.001 for A and C respectively). In parallel, 
there was a decrease in vertical activity (rearing) in the 
first observation period after 3 and 10 mg/kg (Figs 8B, 8D, 
ANOVA F(3,28)=2.2, p<0.11 and F(3,28)=6.44, p=0.002 for B 
and D respectively).
Finally, eltoprazine was tested in contextual fear 
conditioning paradigm allowing testing of learning, i.e., 
A
B
C
Fig.  3. Effect of eltoprazine (injected  s.c. 1  h before the test) on anxiety 
in elevated plus maze expressed as % time in open arms (A) and % open 
arm entries (B). Panel C shows total entries as measure of general activity. 
The values were analyzed using one way ANOVA followed by Dunnett’s 
post‑hoc test and are shown as mean ±SEM. * – P<0.05 vs. vehicle. N=8 
per group.
Fig.  2. Plasma concentrations of eltoprazine after repetitive treatment 
b.i.d (1  mg/kg,  s.c., 14  days) or infusion (8 mg/kg/day, 14  days) using 
osmotic Alzet pumps. Individual values are shown and the horizontal 
lines represent median values. Animals were sacrificed 1 h after the last 
injection or directly after pumps’ explantation. N=8 per group.
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injected before training and tested 24 h later (Fig. 9). In this 
experimental design, we observed lack of significant effect 
of eltoprazine on freezing response at doses up to 5 mg/kg as 
revealed by Kruskal‑Wallis test (ANOVA on ranks, P=0.062). 
However, on the graph a strong trend for disruption can be 
seen at the dose of 5 mg/kg. A direct pairwise comparison 
(Mann‑Whitney test) showed significant difference of this 
group to vehicle confirming that this trend may be an 
expression of real difference. Nevertheless, the dose of 1.25 
and lower can be regards as likely free of this adverse effect 
(Fig. 9).
DISCUSSION
We observed that eltoprazine given repetitively 
or infused to rats produced a decrease of body weight 
of approximately 20–40 g within the study duration 
(2 weeks). At the same time, there was also a substantial 
decrease in food intake. To the best of our knowledge, no 
data have been published on such activity of eltoprazine 
beyond a patent filed by Merz (http://www.google.com.
tr/patents/US20120190690). Dose of eltoprazine shown 
in the present study to affect body weight is similar to, 
or slightly higher than the dose producing antidyskinetic 
effect (Bezard et al. 2013). It remains to be determined 
what the minimal threshold dose showing such activity is, 
as in the present study only one dose per treatment mode 
was employed. The used treatment regimens i.e. injection 
of 1 mg/kg and infusion of 8 mg/kg/day produced 
respectively 220 and 440 nM concentration in plasma. 
Both treatments produced significant effect on weight 
gain, slightly stronger in case of infusion. Since infusion 
better models situation in man, where metabolism is 
slower and steady‑state levels can be achieved this way of 
treatment is more relevant.
Fig.  5. Effect of eltoprazine (injected  s.c.) on anxiety in contextual fear 
conditioning in rats. The animals were exposed to 5 shocks in the test cage 
on day 1 and on day 2 they were injected with eltoprazine and placed again 
in the test cages 1 h later. Freezing was used as a measure of anxiety. The 
values are shown as mean ±SEM. The data were analyzed using ANOVA on 
ranks followed by Mann‑Whitney test. * – P<0.05 vs. vehicle. N=8–9 per group.
A
B
C
Fig.  4. Effect of eltoprazine (injected  s.c. 1  h before the test) on anxiety 
in elevated plus maze under red light conditions expressed as % time in 
open arms (A) and % open arm entries (B). Panel C shows total entries 
as measure of general activity. The values were analyzed using one way 
ANOVA followed by Dunnett’s post‑hoc test and are shown as mean ±SEM 
and. * – P<0.05 vs. vehicle. N=10 per group.
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Fig. 6. Effect of eltoprazine on fear‑potentiated startle in rats. Eltoprazine 
was injected s.c. 1 h before the test. The values are shown as mean ±SEM 
and were analyzed using one‑way ANOVA. There was no significant effect 
of treatment. N=10 per group.
Fig.  7. Effect of eltoprazine on body temperature in rats. Baseline body 
temperature was measured, 60 min later eltoprazine was injected s.c. and 
15  min later temperature measurements were initiated. The values are 
shown as mean ±SEM and were analyzed using two‑way repeated‑measures 
ANOVA with time as repetitive measure followed by Dunnett’s test. 
* – P<0.05 vs. vehicle; # – P<0.05 vs. respective baseline (‑60 min).
A
C
B
D
Fig. 8. Effect of eltoprazine at a low dose range (A, B) and a high dose range (C, D) on horizontal locomotor activity (A, C) and vertical activity (rearings; B, D) 
in rats. The animals were either injected s.c. with eltoprazine and placed in open field 1 h later. The values are shown as mean ±SEM and were analyzed 
using two‑way ANOVA with time as repetitive measure, followed by Dunnett’s post‑hoc test. * – P<0.05 vs. vehicle. N=8 per group.
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The mechanism of action has not been addressed 
in the present study. However, given pharmacological 
profile of eltoprazine, the effect on weight gain and food 
intake could be related to its agonistic action at 5‑HT2C 
receptors. In fact, therapeutic efficacy of fenfluramine 
(indirect 5‑HT agonist) in obesity has previously been 
associated with its effect on 5‑HT2C receptors (Miller 
2005). In fact, this receptor subtype is considered 
a promising candidate for development of anti‑obesity 
drugs, some of which are under development (Marston 
and Heisler 2009) and Belviq (Lorcaserin) relatively 
selective 5‑HT2C agonist has been registered by Arena 
Pharmaceuticals (Brashier et al. 2014).
In the elevated plus maze test we observed a decrease 
in entries into the open arms and the time spent in the 
open arms, which may indicate anxiogenic‑like activity. 
In this test, both illumination intensity and lack of 
walls in two arms contribute to fear and consequently 
to avoiding open arms. The change of experimental 
conditions to red light increased as expected time spent 
in open arms in control animals but has failed to change 
the effect of eltoprazine indicating that it is not related 
to, e.g., photophobia. Previously, Rodgers and colleagues 
(Rodgers et al. 1992) have observed increase in anxiety in 
the plus maze after eltoprazine, an effect similar to that 
of fluprazine, TFMPP and mCPP. In contrast, 8‑OH‑DPAT 
(5‑HT1A agonist) produced anxiolytic effect while CGS 
12066B (5‑HT1B agonist) produced an anxiogenic response 
suggesting that 5‑HT1B receptors are likely contributors 
to the anxiogenic action of eltoprazine. However, in 
another study, chronic treatment with eltoprazine 
increased anxiety in plus maze and also increased 5‑HT2C 
receptors density in the amygdala (Rocha et al. 1994) 
suggesting possible involvement of other subtypes of 
5‑HT receptors as well.
In contrast to the elevated plus maze data, eltoprazine 
administered at low doses produced clear‑cut anxiolytic‑like 
response in the conditioned fear conditioning test. However 
it failed to produce any anxiolytic‑like effect in a test based 
on measuring startle response, i.e., fear potentiated startle 
even at a dose of 1 mg/kg. The reason for this mixed profile in 
anxiety tests is unclear. Based on results from animal models 
of anxiety eltoprazine’s therapeutic potential for anxiety 
treatment is rather weak. 
Eltoprazine also enhances exploration of the white box 
in mice (Sanchez 1997). In stress‑induced hyperthermia 
test, eltoprazine failed to demonstrate any effect (Zethof et 
al. 1995), a finding somewhat contradictory to the results 
of the present study, where dose‑dependent hypothermia 
was observed. Eltoprazine also abolished stress‑induced 
ultrasonic vocalization in adult rats (Sanchez 1993)
Eltoprazine produced dose‑dependent hypothermia 
with a minimal effective dose of 1 mg/kg, which seems 
to be within range decreasing weight gain but slightly 
higher than doses reported to exert antidyskinetic effects 
(0.3 mg/kg) (Paolone et al. 2015). Hyperthermic activity of 
5‑HT1A ligands seems to correlate with the potency and the 
intrinsic activity at the 5‑HT1A receptor (Millan et al. 1993).
In the open field test eltoprazine produced locomotor 
activation starting at 1.25 mg/kg and also a decrease in 
vertical activity (rearings) which is often related. Similarly 
to temperature changes, these effects seem to occur at the 
doses above expected therapeutic range for dyskinesia, but 
at doses active in weight loss.
Eltoprazine, injected before training of CFC, up to 
5 mg/kg did not affect freezing response on the next day 
in the same context, indicating lack of negative effect on 
learning acquisition. It should be noted that a strong trend 
toward impairment was observed which however failed to 
reach significance. Again, this seems to occur at high doses.
In place conditioning test eltoprazine produced place 
aversion dependent on 5‑HT1C receptor antagonists activity 
as it was attenuated by an agonist (Rocha et al. 1993).
CONCLUSIONS
Eltoprazine failed to produce consistent anxiolytic 
activity in animal models but clearly affected weight 
gain and food intake suggesting potential as anti‑obesity 
substance which however needs further investigation 
in dedicated animal models in particular definition of 
minimally effective dose. In turn, it also has to be shown 
that such effects appear at the doses free of adverse 
effects such as change in body temperature and locomotor 
stimulation.
Fig. 9. Effect of eltoprazine on learning in context fear conditioning. The 
animals were injected with eltoprazine (s.c.) and 1  h later exposed to 
5 shocks in the test cage. On the subsequent day the animals were placed 
in the test cages again. Freezing was used as a measure of retention of the 
previously learned context fear. The values are shown as mean ±SEM. The 
data were analyzed using ANOVA on ranks. N=7–8 per group.
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